Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fibrinogen and platelets in patients with acute myeloid leukemia and thrombocytopenia
2019-004295-18Phase 4Terminated
- Sponsor
- Aarhus University Hospital
- Start
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Fibrinogen human in acute myeloid leukemia (AML), Thrombocytopenia and Bleeding, sponsored by Aarhus University Hospital. Primary endpoint: Improvement in clot initiation. Started Nov 2019; status: terminated.
02
Drugs
Fibrinogen human
03
Conditions
acute myeloid leukemia (AML)ThrombocytopeniaBleeding
Beyond the preview
Go deeper on 2019-004295-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004295-18.